“There are today 242 companies plus partners developing 273 drugs targeting melanoma in development.”
Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.
There are today 242 companies plus partners developing 273 drugs targeting melanoma in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 113 drugs. Melanoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 182 different targets. These targets are further categorized on in the software application by 57 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.
How May Drug Pipeline Update Be of Use?
– Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
– Find competitors, collaborations partners, M&A candidates etc.
– Jump start competitive drug intelligence operations
– Excellent starting point for world wide benchmarking
– Compare portfolio and therapy focus with your peers
– Speed up pro-active in-/out licensing strategy work
– Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
Read more here: http://www.heraldonline.com/2012/10/17/4344207/research-and-markets-melanoma.html#storylink=cpy
For more information visit http://www.researchandmarkets.com/research/4rtbvl/melanoma_drug
Leave a Reply